Takeda Pharmaceutical Balance Sheet Health
Financial Health criteria checks 3/6
Takeda Pharmaceutical has a total shareholder equity of ¥6,921.6B and total debt of ¥5,051.2B, which brings its debt-to-equity ratio to 73%. Its total assets and total liabilities are ¥14,573.0B and ¥7,651.4B respectively. Takeda Pharmaceutical's EBIT is ¥653.6B making its interest coverage ratio 6.7. It has cash and short-term investments of ¥859.0B.
Key information
73.0%
Debt to equity ratio
JP¥5.05t
Debt
| Interest coverage ratio | 6.7x |
| Cash | JP¥859.02b |
| Equity | JP¥6.92t |
| Total liabilities | JP¥7.65t |
| Total assets | JP¥14.57t |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: TAK N's short term assets (¥3,054.0B) exceed its short term liabilities (¥2,387.2B).
Long Term Liabilities: TAK N's short term assets (¥3,054.0B) do not cover its long term liabilities (¥5,264.2B).
Debt to Equity History and Analysis
Debt Level: TAK N's net debt to equity ratio (60.6%) is considered high.
Reducing Debt: TAK N's debt to equity ratio has reduced from 103.2% to 73% over the past 5 years.
Debt Coverage: TAK N's debt is not well covered by operating cash flow (17.3%).
Interest Coverage: TAK N's interest payments on its debt are well covered by EBIT (6.7x coverage).